{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=8", "query": { "intervention": "Chemotherapeutic Agent", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 599, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T00:53:35.340Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00691210", "title": "Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Disease", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Niacinamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-06", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2020-11-20", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00691210" }, { "nct_id": "NCT02952508", "title": "Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia", "Multiple Myeloma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Lymphoplasmacytic Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Central Nervous System Lymphoma" ], "interventions": [ { "name": "Iopofosine I 131 single dose", "type": "DRUG" }, { "name": "Iopofosine I 131 multiple dose", "type": "DRUG" }, { "name": "Iopofosine I 131 fractionated dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2017-07-26", "completion_date": "2027-12-22", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 29, "location_summary": "Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952508" }, { "nct_id": "NCT01191775", "title": "A Study of PNT2258 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Lymphoma", "Prostate Cancer", "Melanoma" ], "interventions": [ { "name": "PNT2258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2010-08", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191775" }, { "nct_id": "NCT01204801", "title": "Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Focused Microwave Thermotherapy", "type": "DEVICE" }, { "name": "Chemotherapy (control)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Medifocus, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 238, "start_date": "2010-11", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204801" }, { "nct_id": "NCT00390676", "title": "A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "ADH -1 and carboplatin", "type": "DRUG" }, { "name": "ADH -1 and docetaxel", "type": "DRUG" }, { "name": "ADH -1 and capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adherex Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2006-11", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2010-12-28", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 10, "location_summary": "Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Albany", "state": "New York" }, { "city": "Kettering", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390676" }, { "nct_id": "NCT06696768", "title": "Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Stage III Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Unresectable Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-06-23", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 13, "location_summary": "Gainesville, Florida • Shiloh, Illinois • Fairway, Kansas + 8 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Shiloh", "state": "Illinois" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06696768" }, { "nct_id": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer", "Additional Indications Below for Module 4 and 5", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Bladder Cancer", "Gastric Cancer", "Biliary Cancer", "Cervical Cancer", "Endometrial Cancer", "Small Cell Lung Cancer Only in Module 5" ], "interventions": [ { "name": "AZD5305", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "T- Dxd", "type": "DRUG" }, { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 702, "start_date": "2020-11-12", "completion_date": "2027-05-28", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644068" }, { "nct_id": "NCT07000084", "title": "Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Non-Muscle Invasive Bladder Carcinoma", "Stage 0a Bladder Cancer AJCC v8", "Stage I Bladder Cancer AJCC v8" ], "interventions": [ { "name": "BCG Solution", "type": "BIOLOGICAL" }, { "name": "Biopsy of Bladder", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2025-07-17", "completion_date": "2028-12-05", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07000084" }, { "nct_id": "NCT07285044", "title": "The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis", "Basal Cell Carcinoma", "Biliary Tract Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Fallopian Tube Carcinoma", "Gastroesophageal Junction Carcinoma", "Glioblastoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Hodgkin Lymphoma", "Lung Carcinoma", "Malignant Solid Neoplasm", "Mantle Cell Lymphoma", "Melanoma", "Merkel Cell Carcinoma", "Multiple Myeloma", "Myelodysplastic Syndrome", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Cancer Therapeutic Procedure", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-12-18", "completion_date": "2027-05-15", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285044" }, { "nct_id": "NCT03162224", "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Human Papilloma Virus" ], "interventions": [ { "name": "MEDI0457", "type": "DRUG" }, { "name": "CELLECTRA®5P device", "type": "DEVICE" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 35, "start_date": "2017-06-26", "completion_date": "2021-03-19", "has_results": true, "last_update_posted_date": "2022-08-25", "last_synced_at": "2026-10-14T00:53:35.340Z", "location_count": 14, "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162224" } ] }